The Institute of Scientific Information (ISI, Clativate) listed Amin as one of the world’s most highly cited researchers (under ‘Pharmacology & Toxicology’) in 2017. Amin is also at 0.07% top rank of the Highly Cited Researchers List by Stanford University (published by Elsevier) for Pharmacology. He has published over 350 peer reviewed influential scientific articles (>28000 citations, h-index = 92, Google Scholar) covering various aspects of clinical/translational/systems pharmacology as well as pharmaceutics.
Amin became a full professor in 2007 at the University of Sheffield under the title of Systems Pharmacology (first of such appointment under this name) before moving to University of Manchester at the end of 2008. As the Director of Centre for Applied Pharmacokinetic Research (CAPKR) at the University of Manchester since 2017, Amin collaborates with many pharmaceutical companies with a view to transfer latest scientific knowledge into model-integrated evidence that is necessary for drug development and clinical use. Amin was co-founder of two spin-off companies from the University of Sheffield (Simcyp Limited [now part of Certara Inc]) and Diurnal Limited [now part of Neurocrine Bioscience]). As a leader in the field of physiologically-based pharmacokinetics (PBPK) and Quantitative Systems Pharmacology (QSP), he is internationally recognized and he was one of the founding editors of Pharmacometrics and System Pharmacology in addition to serving on the Editorial Boards of many other pharmacology journals.
As the Senior Vice President of Research & Development (SVP) and Chief Scientific Officer at Certara (since 2014), he facilitates the integration of the latest translational modelling to bio-simulation platforms offered by Certara to its clients, with the aim of accelerating the drug development and regulatory approval.